Accès ouvert
2026
article
OpenAlex
Takahiro Ando, Koki Fujii, Hiroaki Ikushima, Kousuke Watanabe et autres
BACKGROUND: Comprehensive genomic profiling (CGP) can identify oncogenic drivers missed by routine molecular testing in advanced or recurrent non-small cell lung cancer (NSCLC). However, the availability of standard targeted therapy, treatment implementation, and survival relevance of these CGP-identified new drivers remain unclear. …
jp
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Junichi Ishigaki, Ryoko Rikitake, Hidenori Kage, Takahiro Higashi
INTRODUCTION: Thymomas and thymic carcinomas are rare diseases with limited clinical evidence. This study aimed to investigate the clinical characteristics of and treatment practices for Stages III and IV thymoma or thymic carcinoma in Japan. METHODS: We analyzed cases of Stage III …
jp, gb
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Akira Yokoyama, Koh Okamoto, Kiyora Yamashita, Akihisa Mitani et autres
To evaluate the clinical utility of a multi-step fever screening program using infrared thermography (IRT) for visitors to outpatient clinics at a tertiary care hospital during the COVID-19 pandemic. We conducted a single-center, retrospective study at The University of Tokyo Hospital between …
jp
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Keita Goto, Toshiki Kijima, Yusuke Sato, Kousuke Watanabe et autres
ABSTRACT Introduction Neurofibromatosis type 1 (NF1) is a genetic disorder that increases the risk of various tumors. However, its association with testicular germ cell tumors (GCTs) is rare. We report a case of metastatic GCT in an NF1 patient treated with precision …
jp
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Masaaki Yuki, Taro Ishimori, Youichi Shinozaki, Hirofumi Kosuge et autres
BACKGROUND: Pulmonary fibrosis is a chronic progressive lung disease characterized by extensive fibrosis and poor prognosis, highlighting the urgent need for novel therapeutic strategies. This study aims to elucidate the role of the small proteoglycan proline/arginine-rich end leucine-rich repeat protein (PRELP), evaluate …
jp, us, gb
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Hideaki Motomura, Hiroaki Ikushima, Mizuki Fukuchi, Yutaro Ueki et autres
Background Epidermal growth factor receptor (EGFR) exon 20 insertions represent an actionable subset of non–small cell lung cancer (NSCLC), and amivantamab is an available therapeutic option when such mutations are confirmed by companion diagnostics (CDx). However, CDx panels report only predefined sequence-pattern–based …
jp
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Yuhei Suzuki, Hiroaki Ikushima, Mitsuhiro Yamamoto, Yutaro Ueki et autres
Adenoid cystic carcinoma (ACC) is a slow-growing malignancy characterised by late recurrence, making long-term follow-up essential. We report a case of 55-year-old woman who presented with exudative right pleural effusion and subcarinal lymphadenopathy after haematopoietic stem cell transplantation for myelofibrosis. She had …
jp
(code pays fourni par la source)
2026
article
OpenAlex
Hiroaki Ikushima, Kousuke Watanabe, Aya Shinozaki-Ushiku, Katsutoshi Oda et autres
e20713 Background: Methylthioadenosine phosphorylase (MTAP) deletion creates a synthetic lethal vulnerability to protein arginine methyltransferase 5 (PRMT5) and methionine adenosyltransferase 2A (MAT2A) inhibition. While early-phase trials targeting this pathway are ongoing, the clinicogenomic context of MTAP-deleted tumors remains incompletely characterized across diverse …
jp
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Sadakatsu Ikeda, Junichi Matsubara, Kumi Mukai, Masahiro Yoshioka et autres
3134 Background: Comprehensive genomic profiling (CGP) by next-generation sequencing has been reimbursed in Japan since 2019. However, only 8.2% of patients (pts) had received molecularly-matched treatments. One major reason for this limited drug accessibility is that CGP is covered only after progression …
jp
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Hiroaki Ikushima, Hidenori Kage
The homozygous deletion of the chromosome 9p21.3 locus, which includes cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) and methylthioadenosine phosphorylase (MTAP) genes, is one of the most common genomic alterations in cancer. MTAP encodes an essential enzyme in the methionine salvage pathway. Historically, deletions …
jp
(code pays fourni par la source)
2026
article
OpenAlex
H Takumida, Y Mikami, Y Okabe, Y. Terasaki et autres
Abstract Rationale Pleuroparenchymal fibroelastosis (PPFE) is a progressive interstitial pneumonia whose molecular pathology remains poorly defined because surgical biopsy is often infeasible. Cancer-associated fibroblast (CAF) programs—especially myofibroblastic CAFs (myCAFs)—are well described in tumors, but their presence in non-malignant lung fibrosis is unclear. …
jp
(code pays fourni par la source)
2026
article
OpenAlex
Hiroaki Ikushima, Kousuke Watanabe, Aya Shinozaki-Ushiku, Katsutoshi Oda et autres
PURPOSE Methylthioadenosine phosphorylase ( MTAP ) deletion represents a promising therapeutic vulnerability through synthetic lethality. However, the clinical and molecular context of MTAP -deleted thoracic tumors, particularly with respect to actionable oncogenic drivers and immune checkpoint inhibitor efficacy, remains incompletely defined across …
jp
(code pays fourni par la source)